AFLIBERCEPT “EYLEA®” FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN REAL-LIFE ROUTINE CLINICAL PRACTICE
- Authors: Khudaynazarova VS1, Arslanov GM2, Dal’ NY.1, Krasavina MI1, Onishchenko ES1, Panfilova AN1, Chistyakova NV1
-
Affiliations:
- Ophthalmological center “Vision”
- Kazan (Volga region) Federal University
- Issue: Vol 37, No 2 (2018)
- Pages: 84-88
- Section: Articles
- URL: https://journal-vniispk.ru/RMMArep/article/view/14198
- DOI: https://doi.org/10.17816/rmmar14198
- ID: 14198
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
V S Khudaynazarova
Ophthalmological center “Vision”Saint Petersburg, Russia
G M Arslanov
Kazan (Volga region) Federal UniversityKazan, Russia
N Yu Dal’
Ophthalmological center “Vision”Saint Petersburg, Russia
M I Krasavina
Ophthalmological center “Vision”Saint Petersburg, Russia
E S Onishchenko
Ophthalmological center “Vision”Saint Petersburg, Russia
A N Panfilova
Ophthalmological center “Vision”Saint Petersburg, Russia
N V Chistyakova
Ophthalmological center “Vision”Saint Petersburg, Russia
References
- Либман Е. С. Инвалидность вследствие патологии органа зрения. В кн.: Аветисов С. Е., Егоров Е. А., Мошетова Л. К., Нероев В. В., Тахчиди Х. П. Офтальмология. Национальное руководство. М.: ГЭОТАР-Медиа; 2008: 19-26.
- Ferrara N. VEGF-A: a critical regulator of blood vessel growth. Eur. Cytokine Netw. 2009; 20 (4): 158-63.
- Бойко Э. В., Сосновский С. В., Березин Р. Д., Коскин С. А., Ян А. В., Куликов А. Н., Мальцев Д. А., Бутикова О. В., Давыдова В. В., Жукова К. Е.) Антиангиогенная терапия в офтальмологии. СПб.: ВМедА имени С. М. Кирова; 2013).
- Heier J. S. , Brown D. M., Chong V., Korobelnik J. F., Kaiser P. K., Nguyen Q. D., Kirchhof B., Ho A., Ogura Y., Yancopoulos G. D., Stahl N., Vitti R., Berliner A. J., Soo Y., Anderesi M., Groetzbach G., Sommerauer B., Sandbrink R., Simader C., Schmidt-Erfurth U. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology. 2012; 119: 2537-48.
- Thulliez M., Angoulvant D., Pisella P., Bejan-Angoulvant T. Overview of Systematic Reviews and Meta-analyses on Systemic Adverse Events Associated with Intravitreal Anti- Vascular Endothelial Growth Factor Medication Use. JAMA Ophthalmol. 2018. Available at: https://jamanetwork.com/ journals/jamaophthalmology/article-abstract/2676023 (accessed 03.07.2018).
- Talks J. S., Lotery A. J., Ghanchi F., Sivaprasad S., Johnston R. L., Patel N., McKibbin M., Bailey C., Mahmood S. First-Year Visual Acuity Outcomes of Providing Aflibercept According to the VIEW Study Protocol for Age-Related Macular Degeneration. Ophthalmology. 2016; 123 (2): 337-43.
- Lotery A., Griner R., Ferreira A., Milnes F., Dugel P. Real-World Visual Acuity Outcomes between Ranibizumab and Aflibercept in Treatment of Neovascular AMD in a Large US Data Set. Eye. 2017; 1697-706.
- Бойко Э. В., Сосновский С. В., Березин Р. Д., Качерович П. А., Тавтилова Д. А. Интравитреальные инъекции: теория и практика. Офтальмологические ведомости. 2010; 3 (2): 28-35.
- Ashraf M., Souka A. R. Aflibercept in age-related macular degeneration: evaluating its role as a primary therapeutic option. Eye (Lond). 2017; 31 (11): 1523-36.
Supplementary files
